CD59 and pancreatic adenocarcinoma: Disease-free survival (DSS) data, along with the OS results, indicate that patients with KIRC have longer DSS rates, while those with CESC, GBM, HNSC, PAAD, and STAD along with elevated CD59 expression showed shorter DSS rates (Figure S2).